ArticleJournal of drug delivery2011
An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.
Article in Journal of drug delivery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 62 citations in OpenAlex.
- Insight into the Recent Developments of Nanoparticles in Treatment of Cancer and Neuro-Degenerative Disease: A Review.Current topics in medicinal chemistry · 2025Review
- PLGA nanoparticles as an efficient carrier inFrontiers in immunology · 2025Article
- Intradermal Vaccination with PLGA Nanoparticles via Dissolving Microneedles and Classical Injection Needles.Pharmaceutical research · 2024Article
- Effect of vaccine dose onJournal of education and health promotion · 2024Article
- Polymeric Delivery Systems as a Potential Vaccine against Visceral Leishmaniasis: Formulation Development and Immunogenicity.Vaccines · 2023Article
- Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19.Frontiers in bioengineering and biotechnology · 2022Review
- Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.Advanced healthcare materials · 2021Review
- An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.Pharmaceutics · 2021Review
- Self-Assembling Nanovaccine Enhances Protective Efficacy Against CSFV in Pigs.Frontiers in immunology · 2021Article
- Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route.Microbial cell factories · 2019Article
- Peptide-based vaccine successfully induces protective immunity against canine visceral leishmaniasis.NPJ vaccines · 2019Article
- Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and ChronicFrontiers in cellular and infection microbiology · 2018Article
- Development of Peptide Vaccines in Dengue.Current pharmaceutical design · 2018Review
- Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?Pharmaceutical research · 2016Review
- Advanced Nanobiomaterials: Vaccines, Diagnosis and Treatment of Infectious Diseases.Molecules (Basel, Switzerland) · 2016Review
- PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity.Human vaccines & immunotherapeutics · 2016Review
- Peptide/protein vaccine delivery system based on PLGA particles.Human vaccines & immunotherapeutics · 2016Review
- Article
- Vaccine Potentiation by Combination Adjuvants.Vaccines · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of synthetic peptide-based vaccines has many advantages in comparison with vaccines based on live attenuated organisms, inactivated or killed organism, or toxins. Peptide-based vaccines cannot revert to a virulent form, allow a better conservation, and are produced more easily and safely. However, they generate a weaker immune response than other vaccines, and the inclusion of adjuvants and/or the use of vaccine delivery systems is almost always needed. Among vaccine delivery systems, micro- and nanoparticulated ones are attractive, because their particulate nature can increase cross-presentation of the peptide. In addition, they can be passively or actively targeted to antigen presenting cells. Furthermore, particulate adjuvants are able to directly activate innate immune system in vivo. Here, we summarize micro- and nanoparticulated vaccine delivery systems used in the field of synthetic peptide-based vaccines as well as strategies to increase their immunogenicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.